GlassScriptPhysician profile
Thomas L Jeffries
NPI 1114955671
$9,396.06
in general payments reported to CMS, 2019-2025
50 companies · $1,309 in 2025
The $1,309 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,831 · 2020: $1,241 · 2021: $1,087 · 2022: $1,299 · 2023: $1,292 · 2024: $1,337 · 2025: $1,309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,938.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,941.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,330.53 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $839.01 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $791.88 | 2019-2024 | Jardiance, Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $542.92 | 2019-2025 | Jardiance |
| Pfizer INC. | $335.75 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $304.64 | 2019-2022 | |
| Abbott Laboratories | $302.28 | 2023-2024 | Freestyle Libre 3, Proclaim |
| Merck Sharp & Dohme LLC | $298.61 | 2019-2025 | Gardasil 9, Capvaxive, Belsomra |
| Takeda Pharmaceuticals U.S.A., INC. | $277.14 | 2019-2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $186.66 | 2019-2022 | |
| Ibsa Pharma INC. | $184.78 | 2021-2024 | Tirosint, Licart, Licart |
| Optinose US, INC. | $179.61 | 2019-2021 | |
| Amgen INC. | $174.40 | 2019-2024 | Repatha, Otezla |
| Exact Sciences Corporation | $158.67 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Jeffries listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.